TP53 mutations and MLH1 mutations appeared in papillary serous adenocarcinoma, and otherwise KRAS mutations and CDKN2A mutations showed up mainly in mucinous adenocarcinoma (Table 3). This evidence concerns the gene TP53 and papillary serous cystadenocarcinoma.